Table 2 Characteristics for immunotherapy cohorts

Characteristic

CR + PR

SD + PD

p value

CR + PR

SD + PD

p value

Age (years)

0.874

 > 0.999

 < 65

39 (60.94)

75 (62.50)

18 (100)

25 (100)

≥ 65

25 (39.06)

45 (37.50)

0 (0)

0 (0)

Sex

0.308

0.701

 Male

49 (76.56)

83 (69.17)

14 (77.78)

21 (84.00)

 Female

15 (23.44)

37 (30.83)

4 (22.22)

4 (16.00)

Location

0.189

0.624

 Cardia

39 (60.94)

54 (45.00)

6 (33.33)

12 (48.00)

 Body

12 (18.75)

33 (27.50)

5 (27.78)

7 (28.00)

 Antrum

13 (20.31)

31 (25.83)

6 (33.33)

4 (16.00)

 Whole

0 (0.00)

2 (1.67)

1 (5.6)

2 (8.00)

Clinical T stage

0.366

> 0.999

 T3

18 (28.12)

26 (21.67)

0 (0)

0 (0)

 T4

46 (71.88)

94 (78.33)

18 (100)

25 (100)

Clinical N stage

0.457

0.253

 N-

16 (25.00)

24 (20.00)

0 (0)

3 (12.00)

 N+

48 (75.00)

96 (80.00)

18 (100)

22 (88.00)

CA 72−4 level

0.872

> 0.999

 Normal

21 (32.81)

41 (34.17)

4 (22.22)

5 (20.00)

 Abnormal

43 (67.19)

79 (65.83)

14 (77.78)

20 (80.00)

CA 19−9 level

0.498

0.765

 Normal

16 (25.00)

36 (30.00)

7 (38.89)

11 (44.00)

 Abnormal

48 (75.00)

84 (70.00)

11 (61.11)

14 (56.00)

CEA level

0.640

0.099

 Normal

28 (43.75)

48 (40.00)

15 (83.33)

14 (56.00)

 Abnormal

36 (56.25)

72 (60.00)

3 (16.67)

11 (44.00)

Radiomics score *

1.06 (0.69, 1.35)

1.47 (1.18, 1.87)

< 0.001

1.02 (0.03, 1.34)

1.42 (1.00, 1.93)

0.012